Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Exploring the Complement System in Human Disease

M. Kathryn Liszewski and John P. Atkinson, MD  |  Issue: February 2010  |  February 1, 2010

In the crabs, the clotted hemolymph traps the organisms while complement activation coats the bacteria with C3-derived opsonins and liberates the C3a fragment to recruit phagocytes and initiate an inflammatory response. This combination of events is the reason that the complement system is sometimes called “the guardian of the intravascular space.” The AP is truly a simple proteolytic cascade featuring a feedback or amplification loop in which C3 is its central component (see Figure 1, p. 17). The role of the AP in mediating human disease was not appreciated until the past few decades.12,13 Now, it is recognized as an Ab-independent initiator of the acute inflammatory reaction and a potent pathogen recognition system.

The major evolutionary changes that were superimposed on the AP were twofold: one was to facilitate target recognition through Abs, the classical pathway, and lectins, (lectin pathway); the second was the membrane attack (lytic) complex (see Figure 2, p. 17). The AP cascade not only responds to microbes but also to damaged and altered cells and tissues. C3 ticks over at 1% to 2% an hour and, like a sentry, is on guard searching for microbes or damaged self. When it lands on normal self, C3b is inactivated by inhibitors. When it deposits on microbes, unrestricted initial activation is allowed in order to destroy the organism. When it lands on damaged self, a more limited and restricted reaction occurs that is nevertheless sufficient to create an environment for wound repair and to rid the host of the debris.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
TABLE 1: Mutations in Complement System Proteins Associated with aHUS
click for large version

The Critical Need to Control Complement Activation

Because of the design of the feedback loop coupled with its effector capabilities, tight regulation is critical. To this end, nearly half of the proteins of the complement system act to mitigate its effects in plasma (fluid phase, no target) and on healthy host cells (wrong target).14 However, once cells are injured, limited complement activation is desirable to facilitate tissue repair and to provide for safe removal of debris—the so-called “targeted and restricted complement activation.”15

The critical step of C3 cleavage is controlled by regulators that operate through two processes. One mechanism is cofactor activity in which a protein such as the plasma protein factor H (FH) or the nearly ubiquitously expressed membrane cofactor protein (MCP; CD46) binds to C3b (see Figure 3, p. 17). This binding allows a third player, a serine protease of plasma known as factor I, to then degrade C3b. The second process is called decay accelerating activity, in which the catalytic (serine protease) domain of the multiunit C3 convertases is disassociated. These protective mechanisms in large part explain how the complement system separates self from nonself; that is, healthy human tissue is protected, and homeostasis maintained by a constitutively expressed array of regulators on cells and by proteins circulating in plasma. Microbes and damaged cells are not so well shielded. However, a common theme is for opportunistic organisms, especially those that invade the bloodstream, to produce virulence factors that bind the host’s own plasma inhibitors or to synthesize their own CIP mimics.16

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
Figure 2: The complement pathways.
click for large version
Figure 2: The complement pathways. The alternative pathway formed first in evolution. This was followed by addition of the lectin and classical pathways that provided improved target selection and a more efficient enzyme to cleave C3 to C3b.

Dysfunctions of Regulation Leading to Disease Associations

Cellular wastes, including apoptotic and necrotic cells, need to be efficiently eliminated.17 A simple etiologic explanation for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) focuses on the consequences of mishandling of DNA/ RNA protein complexes in the former and citrullinated proteins in the latter. Such biological “garbage” can become an immunogen for an adaptive immune response or a nidus for chronic inflammation. Deposition of debris is associated with several of the most common, serious, and lethal illnesses in the developed world: heart attacks and strokes secondary to atherosclerosis (oxidized lipids); dementia in Alzheimer’s disease from misfolded proteins (amyloid); and vision loss in AMD secondary to lipofuscin pigments (drusen). Chronic tophaceous gout would also be in epidemic form, if it were not for our ability to control uric acid levels.

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:ConditionsEducation & TrainingResearch Rheum Tagged with:complementgeneticsImmunityinflammation

Related Articles

    2015 ACR/ARHP Annual Meeting: Next Generation Sequencing and Disease Mechanisms

    February 17, 2016

    SAN FRANCISCO—By harnessing the power of next generation sequencing strategies and combining them with clever statistical strategies and tools, investigators are striving to define causal pathways of and mechanisms underlying complex diseases, such as rheumatoid arthritis, according to Soumya Raychaudhuri, MD, PhD, associate professor, Harvard Medical School, Brigham and Women’s Hospital, Boston, during a session…

    2015 ACR/ARHP Annual Meeting: Cellular Triggers in Inflammatory Disease

    April 14, 2016

    SAN FRANCISCO—What factors help determine whether or not inflammation resolves, leading to healing, or becomes chronic, leading to disease and tissue destruction? A number of important cells, including toll-like receptors, mast cells, anti-citrullinated protein antibodies, complement and interferon, all play their own role in this process. By understanding how they act in innate and adaptive…

    Case Report: Refractory Calciphylaxis in Lupus

    May 17, 2018

    Calciphylaxis is a poorly understood and life-threatening ischemic vasculopathy characterized by calcification of the small- and medium-size arteries in the skin, subcutaneous tissue and internal organs, which leads to thrombosis, tissue necrosis and painful skin ulcerations that won’t heal. The disease has a 50–80% mortality rate. Although affected patients typically have end-stage renal disease (ESRD)…

    Translating Genetic Discoveries into Rheumatic Therapies

    March 18, 2018

    SAN DIEGO—Will rheumatologists soon be able to use data from genetics and genome-wide association studies to more accurately predict disease and develop new therapies for rheumatic diseases? At a Nov. 5 session at the 2017 ACR/ARHP Annual Meeting, experts shared their views on how to glean this useful knowledge from genomics studies. The cost to develop…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences